Glaukos(GKOS) - 2024 Q3 - Quarterly Report

Financial Performance - For the three months ended September 30, 2024, net sales were $96.7 million, compared to$78.0 million for the same period in 2023, representing a 23.3% increase[108]. - The company incurred net losses of $21.4 million for the three months ended September 30, 2024, compared to a net loss of$30.4 million for the same period in 2023, indicating a 29.5% improvement[107]. - Net sales for Q3 2024 were $96.7 million, a 24$78.0 million in Q3 2023[146]. - The net loss for Q3 2024 was $21.4 million, a 30$30.4 million in Q3 2023[148]. - Net sales for the nine months ended September 30, 2024, were $278.0 million, a 20$232.3 million for the same period in 2023[162]. - The net loss for the nine months ended September 30, 2024, was $112.8 million, compared to a net loss of$97.9 million in the same period of 2023, reflecting a 15% increase[190]. Cost and Expenses - Operating expenses increased to $98.7 million for the three months ended September 30, 2024, compared to$87.5 million for the same period in 2023, reflecting a 12.9% rise[108]. - Cost of sales increased to $22.6 million in Q3 2024 from$18.5 million in Q3 2023, aligning with the increase in net sales[152]. - SG&A expenses rose to $64.0 million in Q3 2024, an increase of 18$54.2 million in Q3 2023[153]. - R&D expenses for Q3 2024 were $34.7 million, up from$33.3 million in Q3 2023, with core R&D expenses at $22.3 million[155]. - Selling, general, and administrative expenses grew by 19$192.2 million, primarily due to increased compensation and discretionary expenses[169][170]. - Research and development expenses decreased to $99.9 million from$101.7 million, influenced by a one-time payment related to the iDose TR NDA[171]. - Non-operating expenses surged to $18.2 million, a 163$6.9 million, largely due to expenses from a Convertible Note exchange[175]. Sales and Market Performance - U.S. glaucoma product sales increased by 35% to $51.6 million in Q3 2024, driven by the introduction of iDose TR and higher demand for the iStent family[147]. - International sales of glaucoma products rose by 21$24.5 million in Q3 2024, reflecting growth in key international markets[148]. - U.S. net sales of glaucoma products increased by 30%, reaching $143.3 million compared to$112.8 million in the prior year[163]. - International sales of glaucoma products rose by 19%, totaling $75.8 million, driven by growth in key markets despite unfavorable foreign exchange rates[164]. Margins and Financial Ratios - Gross margin for the three months ended September 30, 2024, was 77$65.4 million, reflecting a 15% rise from $56.7 million, maintaining a gross margin of 76$100.1 million as of September 30, 2024, up from $93.5 million at the end of 2023[183]. - The company had net working capital of$325.6 million, indicating sufficient current assets to cover short-term liabilities[186]. - For the nine months ended September 30, 2024, net cash from investing activities was $36.0 million, compared to$27.0 million for the same period in 2023, reflecting an increase of approximately 33.3%[196]. - Cash received from stock option exercises and employee stock purchases was $36.9 million in 2024, compared to$12.9 million in 2023, marking an increase of approximately 185.3%[196]. - Financing activities provided $31.4 million of net cash in the nine months ended September 30, 2024, significantly higher than$7.7 million in 2023, representing an increase of approximately 308.9%[196]. Strategic Developments - The company received FDA approval for the iDose TR in December 2023 and began commercialization in February 2024, aiming to enhance treatment options for glaucoma[105]. - The company acquired a clinical-stage biopharma company for $5.0 million in stock and$5.1 million in cash, with potential milestone payments of up to $201.0 million[115]. - A new government tiered rebate structure was negotiated with France's CEPS, expected to reduce rebate accrual rates in 2024 compared to historical levels[114]. - The company closed a transaction to exchange$230.0 million in Convertible Senior Notes for 4,253,423 shares of common stock, reducing the balance of Convertible Notes by $226.7 million[110]. Risks and Future Outlook - Supply chain challenges and inflationary pressures have led to increased costs for certain components and raw materials, which may continue throughout 2024[123]. - The company expects capital expenditures to be modestly lower for the remainder of 2024 as expansion activities related to manufacturing facilities wind down[196]. - The company believes that cash from operating, financing, and investing activities will be sufficient to meet ongoing operations and liquidity requirements for at least the next 12 months[198]. - There have been no significant changes to material cash requirements as of September 30, 2024, compared to disclosures in the Annual Report for the year ended December 31, 2023[198]. - There have been no material changes in exposure to market risk since December 31, 2023[203]. - The company has no off-balance sheet arrangements[197]. - There have been no material changes to critical accounting policies and significant estimates during the three and nine months ended September 30, 2024[202].